Table 1.
Relation between serum miR-193b expression level and the clinicopathologic characteristics of CRC patients
| Variables | Cases | Serum miR-193b levels | P | |
|---|---|---|---|---|
|
|
||||
| Low (n=43) | High (n=47) | |||
| Age | 0.7183 | |||
| <60 | 38 (42.22%) | 19 (21.11%) | 19 (21.11%) | |
| ≥60 | 52 (57.78%) | 24 (26.67%) | 28 (31.11%) | |
| Gender | 0.1021 | |||
| Male | 56 (62.22%) | 23 (25.56%) | 33 (36.67%) | |
| Female | 34 (37.78%) | 20 (22.22%) | 14 (15.56%) | |
| Tumor size (cm) | 0.0590 | |||
| <5 | 63 (70.00%) | 26 (28.89%) | 37 (41.11%) | |
| ≥5 | 27 (30.00%) | 17 (18.89%) | 10 (11.11%) | |
| Depth of invasion | 0.0730 | |||
| T1-T2 | 15 (16.67%) | 4 (4.44%) | 11 (12.22%) | |
| T3-T4 | 75 (83.33%) | 39 (43.33%) | 36 (40.00%) | |
| Lymph node metastasis | 0.0212 | |||
| Negative | 59 (65.56%) | 23 (25.56%) | 36 (40.00%) | |
| Positive | 31 (34.44%) | 20 (22.22%) | 11 (12.22%) | |
| Distant metastasis | 0.1063 | |||
| Negative | 82 (91.11%) | 37 (41.11%) | 45 (50.00%) | |
| Positive | 8 (8.89%) | 6 (6.67%) | 2 (2.22%) | |
| TNM stage | 0.0034 | |||
| I-II | 48 (53.33%) | 16 (17.78%) | 32 (35.56%) | |
| III-IV | 42 (46.67%) | 27 (30.00%) | 15 (16.67%) | |
| Grade | 0.0121 | |||
| I-II | 76 (84.44%) | 32 (35.56%) | 44 (48.89%) | |
| III | 14 (15.56%) | 11 (12.22%) | 3 (3.33%) | |